Randomized, Placebo-Controlled Study of Ethyl-Eicosapentaenoic Acid as Supplemental Treatment in Schizophrenia
- 1 September 2002
- journal article
- clinical trial
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 159 (9) , 1596-1598
- https://doi.org/10.1176/appi.ajp.159.9.1596
Abstract
The study investigated the efficacy and tolerability of ethyl-eicosapentaenoic acid (E-EPA) as add-on treatment in chronic, severe schizophrenia. A randomized, parallel-group, double-blind, placebo-controlled, fixed-dose, add-on study was conducted over 12 weeks. Forty patients with persistent symptoms after at least 6 months of stable antipsychotic treatment received E-EPA or placebo, in addition to their existing treatment. At 12 weeks, the E-EPA group had significantly greater reduction of Positive and Negative Syndrome Scale total scores and of dyskinesia scores than the placebo group. EPA may be an effective and well-tolerated add-on treatment in schizophrenia.Keywords
This publication has 7 references indexed in Scilit:
- A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptomsJournal of Psychiatric Research, 2001
- Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophreniaSchizophrenia Research, 2001
- Are fish oils an effective therapy in mental illness — an analysis of the dataActa Psychiatrica Scandinavica, 2000
- Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophreniaBiological Psychiatry, 2000
- Treatment of schizophrenia in low-income countriesInternational Journal of Neuropsychopharmacology, 1999
- Omega‐3 fatty acid supplementation in schizophrenic patientsHuman Psychopharmacology: Clinical and Experimental, 1996
- Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patientsJournal of Psychiatric Research, 1995